FST344
Follistatin 344
No registered human study names Follistatin 344 as an intervention. ClinicalTrials.gov holds no trial of it, so there is no trial evidence to read — a fact about the public record rather than proof the compound does nothing. No FDA-approved product contains Follistatin 344. 5 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Follistatin 344; the registry search is fuzzy, so every match is re-checked. None of this says whether Follistatin 344 works or is safe.
FDA status
Research only
Human studies
0
Furthest phase
—
Papers, 10 yr
5
Readership
—
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
No registered human study
0
Registered human studies
None
No FDA-approved product contains it
No study of Follistatin 344 in humans is registered on ClinicalTrials.gov. That is a fact about the public record, not a statement that the compound does nothing — but it does mean there is no trial evidence to read, and anyone telling you otherwise should be asked for the registration number. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Follistatin 344 is, and what it has been studied for
Follistatin 344 is tracked here.
No registered trial names Follistatin 344 as an intervention, so there is no condition it has been formally studied in. It does have a literature: 5 indexed papers name it in the last ten years. That work is laboratory and animal research, and a paper is not a trial.
Is anyone studying Follistatin 344?
Papers published each year that name Follistatin 344 in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 1 | 0 | Yes |
| 2018 | 0 | 0 | Yes |
| 2019 | 1 | 0 | Yes |
| 2020 | 2 | 0 | Yes |
| 2021 | 0 | 0 | Yes |
| 2022 | 0 | 0 | Yes |
| 2023 | 0 | 0 | Yes |
| 2024 | 0 | 0 | Yes |
| 2025 | 0 | 0 | Yes |
| 2026 | 1 | 0 | No |
5 papers between 2017 and 2026. A paper counts when “Follistatin 344” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Follistatin 344
5 indexed papers name Follistatin 344 in their title or abstract. These are the 5 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Detection of black market follistatin 344
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
- Detection of black market follistatin 344
- Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series
- The transgenic expression of human follistatin-344 increases skeletal muscle mass in pigs
Collected 2026-08-02from PubMed, phrase-matched on “Follistatin 344” in title and abstract. Run the same search.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.